Obesity as a Risk Factor for Prostatic Enlargement: A Retrospective Cohort Study in Korea
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: We aimed to evaluate obesity, a risk factor of metabolic syndrome, and its association with prostatic enlargement in a retrospective cohort in Korea. Methods: Baseline data were obtained from the Korean Genome and Epidemiology Study on Atherosclerosis Risk of Rural Areas in the Korean General Population (KoGES-ARIRANG). Between March 2015 and November 2015, 2,127 male participants of KoGES-ARIRANG were invited to the Korean Prostate Health Council Screening Program, and 602 participants underwent urological examination, including serum prostate specific antigen measurement and transrectal ultrasonography, and completed the International Prostate Symptom Score questionnaire. The data for 571 participants were analyzed, after excluding 31 men who had a history of prostatic disease or testosterone replacement, or had undergone a prior prostatic surgery or procedure. Results: Among components of metabolic syndrome, waist circumference had a statistically significant linear correlation with incremental increases in prostate volume (B=0.181, P=0.004). Abdominal obesity as determined by anthropometric measures including body mass index (odds ratio [OR], 1.205; 95% confidence interval [CI], 1.088–1.336), waist circumference (OR, 1.073; 95% CI, 1.032–1.115), body fat (OR, 1.126; 95% CI, 1.056–1.202), and visceral fat composition (OR, 1.667; 95% CI, 1.246–2.232) was significantly associated with the presence of high-volume benign prostatic hyperplasia (BPH) (prostate volume≥ 40 mL). Furthermore, the highest quartile of serum leptin (OR, 3.541; 95% CI, 1.103–11.365) and adiponectin levels (OR, 0.315; 95% CI, 0.102–0.971) were significantly correlated with high-volume BPH compared to the lowest quartile of levels. Conclusions: Abdominal obesity and serum leptin level are positively associated with prostate growth, whereas serum adiponectin level is inversely associated with the presence of prostatic enlargement.
Abstract
Purpose: We aimed to evaluate obesity, a risk factor of metabolic syndrome, and its association with prostatic enlargement in a retrospective cohort in Korea. Methods: Baseline data were obtained from the Korean Genome and Epidemiology Study on Atherosclerosis Risk of Rural Areas in the Korean General Population (KoGES-ARIRANG). Between March 2015 and November 2015, 2,127 male participants of KoGES-ARIRANG were invited to the Korean Prostate Health Council Screening Program, and 602 participants underwent urological examination, including serum prostate specific antigen measurement and transrectal ultrasonography, and completed the International Prostate Symptom Score questionnaire. The data for 571 participants were analyzed, after excluding 31 men who had a history of prostatic disease or testosterone replacement, or had undergone a prior prostatic surgery or procedure. Results: Among components of metabolic syndrome, waist circumference had a statistically significant linear correlation with incremental increases in prostate volume (B=0.181, P=0.004). Abdominal obesity as determined by anthropometric measures including body mass index (odds ratio [OR], 1.205; 95% confidence interval [CI], 1.088–1.336), waist circumference (OR, 1.073; 95% CI, 1.032–1.115), body fat (OR, 1.126; 95% CI, 1.056–1.202), and visceral fat composition (OR, 1.667; 95% CI, 1.246–2.232) was significantly associated with the presence of high-volume benign prostatic hyperplasia (BPH) (prostate volume≥ 40 mL). Furthermore, the highest quartile of serum leptin (OR, 3.541; 95% CI, 1.103–11.365) and adiponectin levels (OR, 0.315; 95% CI, 0.102–0.971) were significantly correlated with high-volume BPH compared to the lowest quartile of levels. Conclusions: Abdominal obesity and serum leptin level are positively associated with prostate growth, whereas serum adiponectin level is inversely associated with the presence of prostatic enlargement.
참고문헌 (31)
- 박주현, "Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: A Korean nationwide health insurance database study", Investigative and Clinical Urology, 56(3), pp.233~239 (2015), 대한비뇨기과학회
- 유탁근, "Benign Prostatic Hyperplasia: from Bench to Clinic", Investigative and Clinical Urology, 53(3), pp.139~148 (2012), 대한비뇨기과학회
- Oelke M, "EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction", Eur Urol, 64, pp.118~140 (2013)
- De Nunzio C, "The correlation between metabolic syndrome and prostatic diseases", Eur Urol, 61, pp.560~570 (2012)
- Gacci M, "Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis", BJU Int, 115, pp.24~31 (2015)
- Reaven GM, "Banting lecture 1988. Role of insulin resistance in human disease", Diabetes, 37, pp.1595~1607 (1988)
- Gallagher EJ, "The metabolic syndrome--from insulin resistance to obesity and diabetes", Med Clin North Am, 95, pp.855~873 (2011)
- Smith KB, "Obesity statistics", Prim Care, 43, pp.121~135 (2016)
- Giovannucci E, "Stampfer MJ, et al. Obesity and benign prostatic hyperplasia", Am J Epidemiol, 140, pp.989~1002 (1994)
- Kristal AR, "Race", ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial, 2007, pp.177, 1395~1400
- Dahle SE, "Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia", J Urol, 168, pp.599~604 (2002)
- Terris MK, "Determination of prostate volume by transrectal ultrasound", J Urol, 145, pp.984~987 (1991)
- Matthews DR, "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man", Diabetologia, 28, pp.412~419 (1985)
- Pothiwala P, "Metabolic syndrome and cancer", Metab Syndr Relat Disord, 7, pp.279~288 (2009)
- Gago-Dominguez M, "Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States)", Cancer Causes Control, 13, pp.287~293 (2002)
- MacInnis RJ, "Body size and composition and prostate cancer risk: systematic review and meta-regression analysis", Cancer Causes Control, 17, pp.989~1003 (2006)
- Giovannucci E, "Body mass index and risk of prostate cancer in U.S. health professionals", J Natl Cancer Inst, 95, pp.1240~1244 (2003)
- Jayachandran J, "Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database", Cancer, 115, pp.5263~5271 (2009)
- Natarajan V, "Effects of obesity and weight loss in patients with nononcological urological disease", J Urol, 181, pp.2424~2429 (2009)
- Zou C, "Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients", World J Urol, 34, pp.281~289 (2016)
- Parsons JK, "Metabolic factors associated with benign prostatic hyperplasia", J Clin Endocrinol Metab, 91, pp.2562~2568 (2006)
- Gucalp A, "Targeting obesity-related adipose tissue dysfunction to prevent cancer development and progression", Semin Oncol, 43, pp.154~160 (2016)
- Sarma AV, "Diabetes and benign prostatic hyperplasia", lower urinary tract symptoms: what do we know?, 2009, pp.182(6 Suppl), S32~S37
- Bostanci Y, "Correlation between benign prostatic hyperplasia and inflammation", Curr Opin Urol, 23, pp.5~10 (2013)
- Schenk JM, "Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial", Prostate, 69, pp.1303~1311 (2009)
- Jardé T, "Molecular mechanisms of leptin and adiponectin in breast cancer", Eur J Cancer, 47, pp.33~43 (2011)
- Bub JD, "Adiponectin as a growth inhibitor in prostate cancer cells", Biochem Biophys Res Commun, 340, pp.1158~1166 (2006)
- Combs TP, "Endogenous glucose production is inhibited by the adipose-derived protein Acrp30", J Clin Invest, 108, pp.1875~1881 (2001)
- Tilg H, "Adipocytokines: mediators linking adipose tissue, inflammation and immunity", Nat Rev Immunol, 6, pp.772~783 (2006)
- Bouldin MJ, "The effect of obesity surgery on obesity comorbidity", Am J Med Sci, 331, pp.183~193 (2006)
- Parsons JK, "Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms", Eur Urol, 53, pp.1228~1235 (2008)